Literature DB >> 29715515

Contribution of microRNA-149, microRNA-146a, and microRNA-196a2 SNPs in colorectal cancer risk and clinicopathological features in Tunisia.

Vera Chayeb1, Sana Mahjoub2, Hedia Zitouni3, Hanene Jrah-Harzallah2, Khadija Zouari4, Rached Letaief5, Touhami Mahjoub2.   

Abstract

BACKGROUND AND AIM: Colorectal cancer (CRC) is a worldwide leading cause of mortality. Genetic studies have associated single nucleotide polymorphisms in genes encoding microRNAs with CRC risk but results are mostly inconclusive across variable ethnicities. In this study, we investigated the association of hsa-mir-149 rs2292832 C/T, hsa-mir-146a rs2910164 G/C and hsa-mir-196a2 rs11614913 C/T and explored their roles in clinicopathological features of CRC progression in an Eastern Tunisian cohort. SUBJECTS AND METHODS: Three hundred thirteen subjects were enrolled in our retrospective study including 152 CRC cases and 161 controls. Genotyping was assayed by RFLP-PCR (Restriction Fragment Length Polymorphism-Polymerase Chain Reaction) method. SPSS v.18.0, R and SNP Stats online software performed statistical analysis.
RESULTS: Significantly higher hsa-mir-149C/T rs2292832 minor allele frequency was associated with increased risk of CRC [p = .03; OR = 1.54 (1.08-2.19)]. In addition, significant crude associations of hsa-mir-149C/T rs2292832 polymorphism were detected under codominant, dominant and additive models of inheritance. After adjusting for covariates and performing FDR correction, these associations did not remain. No associations were detected for hsa-mir-146a G/C rs2910164 and hsa-mir-196a2 C/T rs11614913. When performing stratified analysis of clinicopathological features according to genotypes, a significant association (p = .004) was found between hsa-mir-146a G/C rs2910164 and tumour differentiation grade. Regression analysis according to CRC progression features had demonstrated a trend toward significance in overdominant model of inheritance for hsa-mir-149C/T rs2292832 with a protective effect [p = .05; OR = 0.51 (0.26-1.02)].
CONCLUSION: Hsa-mir-149C/T rs2292832 and hsa-mir-146a G/C rs2910164 may influence CRC risk in an ethnicity-dependent manner by interfering with CRC progression parameters in Tunisian cohort.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Differentiation; Metastasis; Single nucleotide polymorphism; Tumor

Mesh:

Substances:

Year:  2018        PMID: 29715515     DOI: 10.1016/j.gene.2018.04.084

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  Lack of association between VEGF -2578C/A polymorphism and risk of colorectal cancer in an Iranian population.

Authors:  Sanaz Savabkar; Neda Zali; Mahrooyeh Hadizadeh; Shabnam Tavangarroosta; Chris Young; Fateme Shojaeian; Nastaran Ebrahimi; Maziar Ashrafian Bonab; Hamid Rezvani; Farzaneh Shalileh; Ehsan Nazemalhosseini-Mojarad
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

2.  Polymorphism rs2682818 participates in the progression of colorectal carcinoma via miR-618-TIMP1 regulatory axis.

Authors:  Wei Shao; Haina Xia; Qiangfang Lan; Jialu Gu; Haidong Huang; Fei Zheng; Youyou Zheng
Journal:  Sci Rep       Date:  2021-11-30       Impact factor: 4.379

3.  Effect of miR-196a2 rs11614913 Polymorphism on Cancer Susceptibility: Evidence From an Updated Meta-Analysis.

Authors:  Md Abdul Aziz; Tahmina Akter; Mohammad Safiqul Islam
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  miR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma.

Authors:  Fengxia Mao; Ju Zhang; Xinru Cheng; Qianya Xu
Journal:  Cancer Cell Int       Date:  2019-12-27       Impact factor: 5.722

Review 5.  Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis.

Authors:  Maria Radanova; Mariya Levkova; Galya Mihaylova; Rostislav Manev; Margarita Maneva; Rossen Hadgiev; Nikolay Conev; Ivan Donev
Journal:  Biomedicines       Date:  2022-01-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.